Protalix BioTherapeutics, Inc. - Common Shares (PLX)

CUSIP: 74365A309

Q2 2024 13F Holders as of 30 Jun 2024

Holder snapshot 7 signals
Share change
-3,852,805
Put/Call ratio
4.5%
SEC-reported price per share
$1.17
Number of holders
64
Value change
-$4,774,740
Number of buys
38
Open additional details 1 more signal available
Number of sells
39
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
79,957,519

Security key

74365A309

Report period

Q2 2024

Institutions

64

Top holders

10

Ownership snapshot

Top reported holders of PLX - Protalix BioTherapeutics, Inc. - Common Shares (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Dexcel Pharma Technologie...
Disclosed value leader
Dexcel Pharma Technologie...
Comparable rows
0/15
Latest evidence
31 Mar 2024
3/4/5 13F Highest disclosed value: $5,128,613 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Dexcel Pharma Technologies Ltd. has the largest disclosed position value at $5.13M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Dexcel Pharma Technologies Ltd.'s linked filing trail.
Disclosed position value Top 5
Dexcel Pharma Technologies Ltd. $5.13M
BlackRock Finance, Inc. $4.17M
STATE STREET CORP $1.04M
RENAISSANCE TECHNOLOGIES LLC $1.04M
GEODE CAPITAL MANAGEMENT, LLC $950.2K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Dexcel Pharma Technologies Ltd.
3/4/5
10%+ Owner
—
denominator unverified
$5,128,613
3,637,314 shares
— 02 Jun 2021
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$4,171,251
3,310,517 shares
— 31 Mar 2024
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$1,041,492
826,581 shares
— 31 Mar 2024
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
—
denominator unverified
$1,039,000
824,700 shares
— 31 Mar 2024
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$950,178
754,110 shares
— 31 Mar 2024
GSA CAPITAL PARTNERS LLP
13F
Company
13F
—
denominator unverified
$622,000
493,571 shares
— 31 Mar 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
64
Shares
5,625,789
Rows available
64
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders
61
Q2 2024 holders
64
Holder diff
3
Investor Q1 2024 Shares Q2 2024 Shares Share Diff Share Chg % Q1 2024 value Q2 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .